63 Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion

Purpose:To provide the clinical recommendations for the administration of intravitreal anti-vascular endothelial growth factor (VEGF) drugs especially bavacizumab for ocular vascular diseases including diabetic macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, retinal vein occlusion and central serous chorioretinopathy.Methods:Twenty clinical questions were developed by the guideline technical committee. Relevant websites and databases were searched to find out the pertinent clinical practice guidelines to answer the questions. The technical committee provided possible answers (scenarios) according to the available evidences for each question. All scenarios along with their levels of evidence and the supported articles were sent to the experts for external review. If the experts did not agree on any of the scenarios for one particular clinical question, the technical committee reviewed all scenarios and their pertinent evidences and made the necessary decision. After that, the experts were asked to score them again. All confirmed scenarios were gathered as the final recommendations.Results:All the experts agreed on at least one of the scenarios. The technical committee extracted the agreed scenario for each clinical question as the final recommendation. Finally, 56 recommendations were developed for the procedure of intravitreal anti-VEGF injection and their applications in the management of ocular vascular diseases.Conclusion:The implementation of this guideline can standardize the management of the common ocular vascular diseases by intravitreal injection of anti-VEGF agents. It can lead to better policy-making and evidence-based clinical decision by ophthalmologists and optimal evidence based eye care for patients.

show abstract

“…Therefore, anti-VEGF agents are the preferred treatment in these cases. [ 141 142 143 144 145 146 147 148 ] EL: I…”

Section: Resultsmentioning

confidence: 99%

Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline

Nikkhah¹,

Karimi²,

Ahmadieh³

et al. 2018

J Ophthalmic Vis Res

View full text Add to dashboard Cite

show abstract

The Results of Intravitreal Bevacizumab Injections and Laser Photocoagulation for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion

Yılmaz

Yazıcı

Demirok

et al. 2015

BJMMR

View full text Add to dashboard Cite

63 Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion

Abstract: Intravitreal bevacizumab is an effective and safe drug for reducing ME and improving visual acuity secondary to RVO in the short term follow up.

Cited by 2 publications

References 16 publications

Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline

Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline

The Results of Intravitreal Bevacizumab Injections and Laser Photocoagulation for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion

Contact Info

Product

Resources

About